Pharmacy Department, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
JCO Oncol Pract. 2024 Sep;20(9):1219-1230. doi: 10.1200/OP.23.00694. Epub 2024 Jun 7.
Implementation science endeavors to facilitate the translation of evidence-based research into clinical routine. The clinical pharmacological/pharmaceutical care program evaluated in the randomized AMBORA trial on medication safety with oral antitumor therapeutics (OAT) optimizes care delivery and provides significant benefits for patients, treatment teams, and health care systems. Thus, we aimed to investigate the implementation of this care program within the AMBORA Competence and Consultation Center (AMBORA Center).
The AMBORA Center within a University Comprehensive Cancer Center offered several services (eg, patient consultations) and was evaluated according to the RE-AIM framework. This multicenter hybrid type III trial focused on implementation outcomes (eg, patient recruitment, referring units, evaluation of services) while concurrently investigating effectiveness (eg, side effects, medication errors). Quantitative and qualitative assessments were combined.
The AMBORA Center conducted over 800 consultations with 420 patients in seven institutions. The primary end point of counseling 70% of patients treated with OAT was not reached. Patients were referred by 15 treatment units compared with 11 units in the AMBORA trial. On the basis of heterogeneous referral rates and characteristics across the institutions, barriers and facilitators of the implementation process were derived. Several survey results (eg, stakeholder interviews, online/paper-based questionnaires) reflected a high appreciation of services by patients and health care professionals. The severity of 60.1% (178 of 296) of detected side effects improved, and 86.3% (297 of 344) of medication errors were resolved.
Despite not reaching the primary implementation outcome, the AMBORA Center included more treatment units and demonstrated patient benefit of the AMBORA care program by meeting all effectiveness outcomes. We outlined quantitative and qualitative implementation characteristics to enhance outreach and foster further dissemination of centers to optimize medication safety with OAT.
实施科学努力促进循证研究向临床常规转化。在口服抗肿瘤治疗药物(OAT)药物安全方面进行的随机 AMBORA 试验评估的临床药理学/药学护理计划优化了护理服务的提供,并为患者、治疗团队和医疗保健系统带来了显著益处。因此,我们旨在调查该护理计划在 AMBORA 能力和咨询中心(AMBORA 中心)中的实施情况。
大学综合癌症中心内的 AMBORA 中心提供了多项服务(例如,患者咨询),并根据 RE-AIM 框架进行了评估。这项多中心混合 III 期试验侧重于实施结果(例如,患者招募、转介单位、服务评估),同时调查有效性(例如,副作用、用药错误)。将定量和定性评估相结合。
AMBORA 中心在七个机构中为 420 名患者进行了 800 多次咨询。未达到为 70%接受 OAT 治疗的患者提供咨询的主要终点。与 AMBORA 试验中的 11 个单位相比,有 15 个治疗单位转介了患者。根据机构之间不同的转诊率和特征,得出了实施过程的障碍和促进因素。多项调查结果(例如,利益相关者访谈、在线/纸质问卷)反映了患者和医疗保健专业人员对服务的高度赞赏。所发现的 60.1%(178/296)副作用的严重程度得到改善,86.3%(297/344)的用药错误得到解决。
尽管未达到主要的实施结果,但 AMBORA 中心纳入了更多的治疗单位,并通过达到所有有效性结果,证明了 AMBORA 护理计划对患者的益处。我们概述了定量和定性的实施特征,以扩大服务范围,促进更多中心的传播,从而优化 OAT 的药物安全性。